	Application No.	Applicant(a)
. Nation of Allowability	Application No.	Applicant(s)
	10/644,277	GUDAS ET AL.
Notice of Allowability	Examiner	Art Unit
	Parithosh K. Tungaturthi	1643
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>11/25/2006</u> .		
2. The allowed claim(s) is/are <u>1,2,41-46,51 and 53-82</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 		
		•
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	• •
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	
3. ☐ Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Dat 7. ⊠ Examiner's Amendn	nent/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	•
	TIMES	SHEELA HU

Application/Control Number: 10/644,277 Page 2

Art Unit: 1643

1971). See also MPEP § 804.01.

EXAMINER'S AMENDMENT

1. Claims 1, 2, 41 and 44 are allowable. Claims 42, 43, 45-48 and 53, previously withdrawn from consideration as a result of a restriction requirement, require all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement between Groups XV and Groups XXXVIII-XXXX, as set forth in the Office action mailed on 09/20/2005, is hereby withdrawn and claims 42, 43, 45-48 and 53 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer

applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA

Application/Control Number: 10/644,277 Page 3

Art Unit: 1643

2. Authorization for this examiner's amendment was given in a telephone interview

with Ms. Mallary K. de Merlier on 11/29/2006.

3. Claims 47 and 48 have been cancelled.

In claim, line 1, the word "effectively" has been deleted.

In claims 79-82, the phrase "antibody binding fragment" in line 1 of each claim

has been amended to "...antigen binding fragment....".

Reasons for allowance:

4. The support for "antigen binding fragment" can be found in paragraph 76 (in

particular), wherein the specification discloses that binding fragments include Fab, Fab',

F(ab').sub.2, Fv, and single-chain antibodies

5. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Parithosh K. Tungaturthi whose telephone number is

571-272-8789. The examiner can normally be reached on Monday through Friday from

8:30 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Larry R. Helms, Ph.D. can be reached on (571) 272-0832. The fax phone

number for the organization where this application or proceeding is assigned is 571-

273-8300.

Respectfully, Parithosh K. Tungaturthi, Ph.D. Ph: (571) 272-8789

PRIMARY EXAMINER

Page 4